An exome-wide sequencing study of lipid response to high-fat meal and fenofibrate in Caucasians from the GOLDN cohort[S]

Our understanding of genetic influences on the response of lipids to specific interventions is limited. In this study, we sought to elucidate effects of rare genetic variants on lipid response to a high-fat meal challenge and fenofibrate (FFB) therapy in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) cohort using an exome-wide sequencing-based association study. Our results showed that the rare coding variants in ITGA7, SIPA1L2, and CEP72 are significantly associated with fasting LDL cholesterol response to FFB (P = 1.24E-07), triglyceride postprandial area under the increase (AUI) (P = 2.31E-06), and triglyceride postprandial AUI response to FFB (P = 1.88E-06), respectively. We sought to replicate the association for SIPA1L2 in the Heredity and Phenotype Intervention (HAPI) Heart Study, which included a high-fat meal challenge but not FFB treatment. The associated rare variants in GOLDN were not observed in the HAPI Heart study, and thus the gene-based result was not replicated. For functional validation, we found that gene transcript level of SIPA1L2 is associated with triglyceride postprandial AUI (P < 0.05) in GOLDN. Our study suggests unique genetic mechanisms contributing to the lipid response to the high-fat meal challenge and FFB therapy.

[1]  P. Bork,et al.  Human non-synonymous SNPs: server and survey. , 2002, Nucleic acids research.

[2]  N. Martin,et al.  Heritabilities of apolipoprotein and lipid levels in three countries. , 2002, Twin research : the official journal of the International Society for Twin Studies.

[3]  Steven Henikoff,et al.  SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..

[4]  X. Adiconis,et al.  Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants: The GOLDN Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[5]  G. Fodor.  Primary prevention of CVD: treating dyslipidaemia. , 2008, BMJ clinical evidence.

[6]  J. O’Connell,et al.  The genetic response to short-term interventions affecting cardiovascular function: rationale and design of the Heredity and Phenotype Intervention (HAPI) Heart Study. , 2008, American heart journal.

[7]  D. Allison,et al.  The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions , 2008, Journal of Human Genetics.

[8]  S. Browning,et al.  A Groupwise Association Test for Rare Mutations Using a Weighted Sum Statistic , 2009, PLoS genetics.

[9]  D. Allison,et al.  Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the Genetics of Lipid-Lowering Drugs and Diet Network study , 2009, Pharmacogenetics and genomics.

[10]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[11]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[12]  X. Chu,et al.  Common polymorphisms in ITGA2, PON1 and THBS2 are associated with coronary atherosclerosis in a candidate gene association study of the Chinese Han population , 2010, Journal of Human Genetics.

[13]  M. Wojczynski,et al.  Comparison of Postprandial Responses to a High-Fat Meal in Hypertriglyceridemic Men and Women before and after Treatment with Fenofibrate in the Genetics and Lipid Lowering Drugs and Diet Network (GOLDN) Study. , 2010, SRX pharmacology.

[14]  Lee-Jen Wei,et al.  Pooled Association Tests for Rare Variants in Exon-Resequencing Studies , 2010 .

[15]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[16]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[17]  H. Tiwari,et al.  Apolipoprotein E Polymorphisms and Postprandial Triglyceridemia Before and After Fenofibrate Treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study , 2010, Circulation. Cardiovascular genetics.

[18]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[19]  Aleksandar Milosavljevic,et al.  An integrative variant analysis suite for whole exome next-generation sequencing data , 2012, BMC Bioinformatics.

[20]  Gonçalo R. Abecasis,et al.  The variant call format and VCFtools , 2011, Bioinform..

[21]  Xihong Lin,et al.  Rare-variant association testing for sequencing data with the sequence kernel association test. , 2011, American journal of human genetics.

[22]  J. Kastelein,et al.  Lipid parameters for measuring risk of cardiovascular disease , 2011, Nature Reviews Cardiology.

[23]  Jacob A. Tennessen,et al.  Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.

[24]  I. Borecki,et al.  Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate , 2012, PloS one.

[25]  Mauricio O. Carneiro,et al.  From FastQ Data to High‐Confidence Variant Calls: The Genome Analysis Toolkit Best Practices Pipeline , 2013, Current protocols in bioinformatics.

[26]  I. Borecki,et al.  The PPAR Alpha gene is associated with triglyceride, low-density cholesterol, and inflammation marker response to fenofibrate intervention: The GOLDN Study , 2012, The Pharmacogenomics Journal.

[27]  Tanya M. Teslovich,et al.  Discovery and refinement of loci associated with lipid levels , 2013, Nature Genetics.

[28]  Shuang Feng,et al.  RAREMETAL: fast and powerful meta-analysis for rare variants , 2014, Bioinform..

[29]  Jennifer G. Robinson,et al.  Whole-exome sequencing identifies rare and low-frequency coding variants associated with LDL cholesterol. , 2014, American journal of human genetics.

[30]  L. Liang,et al.  Epigenome-Wide Association Study of Fasting Blood Lipids in the Genetics of Lipid-Lowering Drugs and Diet Network Study , 2014, Circulation.

[31]  J. Borén,et al.  Postprandial hypertriglyceridemia as a coronary risk factor. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[32]  Dajiang J. Liu,et al.  Meta-Analysis of Gene Level Tests for Rare Variant Association , 2013, Nature Genetics.

[33]  Sara M. Willems,et al.  The impact of low-frequency and rare variants on lipid levels , 2015, Nature Genetics.

[34]  I. Borecki,et al.  Genome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN). , 2015, Metabolism: clinical and experimental.

[35]  J. O’Connell,et al.  Evidence for several independent genetic variants affecting lipoprotein (a) cholesterol levels. , 2015, Human molecular genetics.

[36]  D. Gudbjartsson,et al.  Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease , 2016, Nature Genetics.

[37]  Skylar W. Marvel,et al.  A genome-wide study of lipid response to fenofibrate in Caucasians: a combined analysis of the GOLDN and ACCORD studies , 2016, Pharmacogenetics and genomics.

[38]  Michael J Bamshad,et al.  Guidelines for Large-Scale Sequence-Based Complex Trait Association Studies: Lessons Learned from the NHLBI Exome Sequencing Project. , 2016, American journal of human genetics.